FDA approves oral version of Wegovy
Novo Nordisk A/S has become the first developer of a weight loss drug to have its medicine approved by the US Food and Drug Administration as a pill. The decision, announced on 22 December, enables Wegovy (semaglutide) to be administered orally, in addition to its four earlier approvals as an injectable treatment. This puts the Danish company in a stronger position than before, relative to its competitor Eli Lilly and Co which only recently submitted an oral obesity treatment to the FDA for review.
